Create Free Account

By creating account you will get access to hot stocks & personalised emails

Sangamo Therapeutics Inc

Healthcare US SGMO

2.315USD
-0.035(1.49%)

Last update at 2024-12-19T18:55:00Z

Day Range

2.242.82
LowHigh

52 Week Range

0.291.67
LowHigh

Fundamentals

  • Previous Close 2.35
  • Market Cap128.93M
  • Volume18552182
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-212.39200M
  • Revenue TTM18.76M
  • Revenue Per Share TTM0.11
  • Gross Profit TTM -138.59900M
  • Diluted EPS TTM-1.97

Analyst Recommendations

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -191.84900M -177.99100M -120.77700M -95.41900M -68.88900M
Minority interest 0.00000M -0.01100M -0.12600M -0.23300M -0.55500M
Net income -192.27800M -178.29700M -121.12200M -75.81800M -68.33400M
Selling general administrative 62.68M 63.22M 67.10M 61.69M 46.74M
Selling and marketing expenses - - - - -
Gross profit 111.30M 110.70M 118.19M 102.43M 84.45M
Reconciled depreciation 20.56M 17.64M 13.37M 9.61M 2.36M
Ebit -221.84300M -200.97500M -142.92100M -114.78700M -79.50900M
Ebitda -201.28100M -183.33700M -129.55200M -105.18000M -77.15000M
Depreciation and amortization 20.56M 17.64M 13.37M 9.61M 2.36M
Non operating income net other 9.43M 5.35M 8.78M 9.76M 8.26M
Operating income -201.28100M -183.33700M -129.55200M -105.18000M -77.15000M
Other operating expenses 312.58M 294.04M 247.74M 207.61M 161.60M
Interest expense -9.43200M 23.00M 22.27M 0.00000M 0.00000M
Tax provision 0.43M 0.31M 0.34M 0.00000M 0.00000M
Interest income 9.43M 5.35M 8.78M 9.76M 8.26M
Net interest income 9.43M 5.35M 8.78M 9.76M 8.26M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.43M 0.31M 0.34M -19.60100M 8.26M
Total revenue 111.30M 110.70M 118.19M 102.43M 84.45M
Total operating expenses 312.58M 294.04M 247.74M 207.61M 161.60M
Cost of revenue - - - 145.92M 114.87M
Total other income expense net 9.43M 5.35M 8.78M 9.76M 8.26M
Discontinued operations - - - - -
Net income from continuing ops -192.27800M -178.29700M -121.12200M -95.41900M -68.88900M
Net income applicable to common shares -192.27800M -178.28600M -120.99600M -95.18600M -68.33400M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 165.32M 562.51M 721.92M 938.55M 637.52M
Intangible assets - 50.73M 53.76M 58.13M 53.16M
Earning assets - - - - -
Other current assets 12.00M 18.22M 15.86M 11.99M 5.41M
Total liab 82.43M 267.55M 346.58M 441.18M 204.78M
Total stockholder equity 82.89M 294.96M 375.34M 497.37M 432.74M
Deferred long term liab - 6.27M 6.64M 7.18M 6.57M
Other current liab 27.88M 33.39M 28.39M 30.66M 21.28M
Common stock 1.78M 1.67M 1.46M 1.42M 1.16M
Capital stock 1.78M 1.67M 1.46M 1.42M 1.16M
Retained earnings -1406.37600M -1148.54500M -956.26700M -777.98100M -656.98500M
Other liab - 116.85M 174.64M 259.24M 93.71M
Good will 0.00000M 37.55M 39.70M 42.80M 39.27M
Other assets 0.00000M 18.52M 16.82M 15.06M 10.57M
Cash 45.20M 100.44M 178.87M 131.33M 80.43M
Cash and equivalents - - - - -
Total current liabilities 47.73M 111.71M 127.89M 143.55M 69.87M
Current deferred revenue - 51.78M 85.71M 96.64M 38.71M
Net debt -7.10000M -57.33600M -130.79100M -89.24300M -36.02200M
Short term debt 4.59M 4.12M 4.03M 3.69M 3.21M
Short long term debt - - - - -
Short long term debt total 38.10M 43.11M 48.08M 42.09M 44.41M
Other stockholder equity 1492.08M 1450.24M 1334.14M 1268.51M 1091.01M
Property plant equipment - 63.53M 51.52M 41.32M 29.93M
Total current assets 94.33M 300.33M 398.77M 659.67M 405.47M
Long term investments 0.00000M 29.84M 88.17M 50.53M 21.83M
Net tangible assets - 206.68M 281.88M 397.31M 340.12M
Short term investments 35.80M 177.19M 197.68M 510.09M 282.05M
Net receivables 1.33M 4.47M 6.36M 6.26M 37.59M
Long term debt - - - - -
Inventory - - -88.16900M -50.53000M -22.51400M
Accounts payable 15.26M 22.42M 9.76M 12.55M 6.67M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - -0.86800M 0.18M
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -4.59500M -8.40400M -3.98700M 5.42M -2.44900M
Additional paid in capital - - - - -
Common stock total equity - 1.67M 1.46M 1.42M 1.16M
Preferred stock total equity - - - - -
Retained earnings total equity - -1148.54500M -956.26700M -777.98100M -656.98500M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 16.63M 12.25M 10.17M 7.87M 4.00M
Deferred long term asset charges - - - - -
Non current assets total 70.99M 262.18M 323.15M 278.88M 232.04M
Capital lease obligations 38.10M 43.11M 48.08M 42.09M 44.41M
Long term debt total - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments 158.44M 79.46M 271.60M -256.20900M -38.86400M
Change to liabilities - 14.28M -6.07500M 18.88M 3.69M
Total cashflows from investing activities - 59.28M 248.20M -271.62700M -59.80100M
Net borrowings - - - - -
Total cash from financing activities 14.59M 84.66M 32.86M 153.10M 142.03M
Change to operating activities - -6.67100M -9.24000M -6.34800M -0.88900M
Net income -257.83100M -192.27800M -178.29700M -121.12200M -95.41900M
Change in cash -55.24000M -78.42800M 47.54M 50.90M -61.99000M
Begin period cash flow 100.44M 180.37M 132.83M 81.93M 143.92M
End period cash flow 45.20M 101.94M 180.37M 132.83M 81.93M
Total cash from operating activities -224.84200M -223.62700M -233.25100M 169.88M -144.40200M
Issuance of capital stock 33.73M 84.87M 27.10M 142.53M 136.31M
Depreciation 22.19M 20.56M 17.64M 13.37M 9.61M
Other cashflows from investing activities - - -0.11900M -0.70400M -0.26200M
Dividends paid - - - - -
Change to inventory - - 7.66M -10.70300M 4.19M
Change to account receivables 3.15M 2.33M -0.78900M 31.68M -32.23600M
Sale purchase of stock -1.45300M -2.10400M 3.37M -0.76500M 2.04M
Other cashflows from financing activities 16.04M 86.76M 2.39M 153.87M 3.68M
Change to netincome - 31.65M 32.90M 25.93M 19.40M
Capital expenditures 21.16M 20.17M 23.28M 14.71M 20.68M
Change receivables - 1.89M -0.10300M 31.33M -32.54300M
Cash flows other operating - -90.03500M -93.96300M 210.00M -38.74600M
Exchange rate changes - - - - -
Cash and cash equivalents changes - -79.68200M 47.81M 51.35M -62.17400M
Change in working capital -164.03400M -82.31900M -101.89500M 252.59M -73.01000M
Stock based compensation 27.36M 31.65M 32.96M 25.71M 19.33M
Other non cash items 153.80M -1.24200M -6.42700M -0.66600M 0.22M
Free cash flow -245.99700M -243.79800M -256.52900M 155.16M -165.07700M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
SGMO
Sangamo Therapeutics Inc		 -0.035 1.49% 2.31 - - 0.63 1.35 0.39 -0.7145
NVO
Novo Nordisk A/S		 -2.26 2.13% 103.70 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -1.68 1.57% 105.12 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -55.6951 12.45% 391.80 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 -4.445 0.62% 710.17 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California.

Sangamo Therapeutics Inc

501 Canal Blvd, Richmond, CA, United States, 94804

Key Executives

Name Title Year Born
Dr. Alexander D. Macrae Ch.B, M.B., MRCP, Ph.D. CEO, Pres & Director 1963
Ms. Prathyusha Duraibabu CPA, M.B.A. Sr. VP, CFO & Principal Accounting Officer 1979
Mr. D. Mark McClung Exec. VP & COO 1963
Dr. R. Andrew Ramelmeier Ph.D. Exec. VP of Technical Operations 1962
Dr. Jason D. Fontenot Ph.D. Sr. VP & Chief Scientific Officer 1970
Ms. Aron Feingold Head of Corp. Communications & Investor Relations Officer NA
Mr. Scott B. Willoughby Sr. VP, Gen. Counsel & Corp. Sec. 1975
Ms. Whitney Jones Sr. VP & Chief People Officer NA
Dr. Nathalie Dubois-Stringfellow Ph.D. Chief Devel. Officer NA
Ms. Heather Erickson Chief of Staff NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.

Our Company

Useful Links

Contact Us

ISO Certified Market Research

Kalkine Solutions Private Limited, authorized representative of Kalkine Pty Ltd, holds ISO 27001:2022 certification bearing Certificate No.- IC-IS-2404072

Our Company

Useful Links

Contact Us

Disclaimer

The information given by Kalkine Pty Ltd ABN34 154 808 312 (Australian Financial Services License Number 425376) on this website is general information or advice only.

It does not take into account any of your personal objectives, circumstances or needs. Choosing an investment is an important decision. If you do not feel confident making a decision based on the recommendations Kalkine has made in our reports, you should consider obtaining personal advice from an authorised adviser.

There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. Terms & Conditions have been provided for our services, please go through them and also read our Financial Services Guide.

Our website may contain information on past performance of particular investments. Past performance is not an indicator of future performance. Hypothetical returns may not reflect actual performance. Any displays of potential investment opportunities are for sample purposes only and may not actually be available to investors.

The information on the website does not constitute an offer to sell securities or a solicitation of an offer to buy securities. Our reports contain general recommendations to invest in securities.

Copyright 2024 Krish Capital Pty. Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.